Structural basis for the inhibition of the HCoV-NL63 main protease Mpro by X77
Biochemical and Biophysical Research Communications · 2024
DOI: 10.1016/j.bbrc.2024.150231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024. Verfasst von Jie Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Thera…. Hauptthemen laut MEDLINE: Coronavirus NL63, Human, SARS-CoV-2, Coronavirus 3C Proteases, Antiviral Agents. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Key Research and Development Program of Jiangxi Province, Gannan Medical University, Guangxi Key Research and Development Program.
Abstract (Originalsprache)
Human coronaviruses are a group of pathogens that primarily cause respiratory and intestinal diseases. Infection can easily cause respiratory symptoms, as well as a variety of serious complications. There are several types of human coronaviruses, such as SARS-CoV, MERS-CoV, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, and SARS-CoV-2. The prevalence of COVID-19 has led to a growing focus on drug research against human coronaviruses. The main protease (Mpro) from human coronaviruses is a relatively conserved that controls viral replication. X77 was discovered to have extremely high inhibitory activity against SARS-CoV-2 Mpro through the use of computer-simulated docking. In this paper, we have resolved the crystal structure of the HCoV-NL63 Mpro complexed with X77 and analyzed their interaction in detail. This data provides essential information for solving their binding modes and their structural determinants. Then, we compared the binding modes of X77 with SARS-CoV-2 Mpro and HCoV-NL63 Mpro in detail. This study illustrates the structural basis of HCoV-NL63 Mpro binding to the inhibitor X77. The structural insights derived from this study will inform the development of new drugs with broad-spectrum resistance to human coronaviruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
- Applied Biology Laboratory, College of Pharmaceutical and Biological Engineering, Shenyang University of Chemical Technology, Shenyang, 110142, China.
- College of Pharmaceutical Sciences, Gannan Medical University, Ganzhou, 341000, China.
- College of Pharmaceutical Sciences, Gannan Medical University, Ganzhou, 341000, China. Electronic address: rmsl_2040@163.com.
Förderung
- Key Research and Development Program of Jiangxi Province
- Gannan Medical University
- Guangxi Key Research and Development Program
- National Natural Science Foundation of China
- Double Thousand Plan of Jiangxi Province
- Jiangxi Provincial Natural Science Foundation
Zitieren
APA
Xu, J., Zhu, Q., Li, W., Yin, X., & Li, J. (2024). Structural basis for the inhibition of the HCoV-NL63 main protease Mpro by X77. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2024.150231
Vancouver
Xu J, Zhu Q, Li W, Yin X, Li J. Structural basis for the inhibition of the HCoV-NL63 main protease Mpro by X77. Biochemical and Biophysical Research Communications. 2024. doi:10.1016/j.bbrc.2024.150231
BibTeX
@article{Xu2024,
author = {Xu, Jie and Zhu, Qinyao and Li, Wenwen and Yin, Xiushan and Li, Jian},
title = {Structural basis for the inhibition of the HCoV-NL63 main protease Mpro by X77},
journal = {Biochemical and Biophysical Research Communications},
year = {2024},
doi = {10.1016/j.bbrc.2024.150231}
}
EUVIMED